Metraipolis › archive › dc_6d4e8b6cb666

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML — Europe PMC PMID:40706052

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40706052
DOI
10.1182/bloodadvances.2025016399
License (as archived)
solo-consultazione
Archived
2026-10-08T06:45:35.535Z
SHA-256 of the archived text
d0037da60d76cb070734b02e465a14e2b3ef16fb4868eb8c3c659911c8fa8cee
Stable URL of this page
https://metraipolis.com/documento/dc_6d4e8b6cb666

How to cite

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML — Europe PMC PMID:40706052 — Europe PMC (en), https://europepmc.org/article/MED/40706052 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6d4e8b6cb666 (Metraipolis archive dc_6d4e8b6cb666, sha256 d0037da60d76cb070734b02e465a14e2b3ef16fb4868eb8c3c659911c8fa8cee)
BibTeX
@misc{dc6d4e8b6cb666,
  title = {Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML — Europe PMC PMID:40706052},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40706052},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6d4e8b6cb666; sha256 d0037da60d76cb070734b02e465a14e2b3ef16fb4868eb8c3c659911c8fa8cee},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40706052. Agents can read the archived copy with the MCP tool read_document.